Andrew J Lloyd1, Sarah Dewilde2, Simon Noble3, Elisabeth Reimer4, Agnes Y Y Lee5. 1. Acaster Lloyd Consulting Ltd., Oxford, UK. Electronic address: andrew.lloyd@acasterlloyd.com. 2. Services in Health Economics, Brussels, Belgium. 3. Cardiff University, Cardiff, UK. 4. Leo Pharma A/S, Ballerup, Denmark. 5. Division of Hematology, University of British Columbia and British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Abstract
BACKGROUND: Venous thromboembolism (VTE) is common in cancer patients and its treatment is associated with a high risk of recurrent VTE (rVTE) and bleeding. OBJECTIVES: To analyze data from the Comparison of Acute Treatments in Cancer Hemostasis (CATCH) trial to describe the impact of rVTE and bleeding events on health-related quality of life. METHODS: The three-level EuroQol five-dimensional questionnaire (EQ-5D) data were collected monthly for up to 7 months in patients starting anticoagulation for newly diagnosed VTE. Analyses were designed to describe the impact of rVTE and bleeding on EQ-5D scores while controlling for effects of covariates such as background and clinical variables and longitudinal changes. A repeated-measures model with specification of the variance-covariance matrix to characterize the intrapatient correlation was used to estimate the utility values. The impact of an rVTE or a bleeding event was assumed to be reflected in the utility value when it occurred within 2 weeks from a planned data collection point. RESULTS: Data were available from 883 patients. A total of 76 rVTE and 159 bleeding events occurred during follow-up. rVTE had a significant impact on EQ-5D scores, with a decrement of -0.075 on the basis of our reference case (male, no metastasis, Eastern Cooperative Oncology Group score = 1, Western European), but different patients might have different decrements. Bleeding events had a smaller (nonstatistically significant) impact on EQ-5D scores. CONCLUSIONS: This data set study has quantified the decline in EQ-5D scores associated with experiencing rVTE or bleeding events in cancer patients. These results indicate the net gain in quality of life and impact on cost-effectiveness of secondary VTE prevention.
BACKGROUND: Venous thromboembolism (VTE) is common in cancer patients and its treatment is associated with a high risk of recurrent VTE (rVTE) and bleeding. OBJECTIVES: To analyze data from the Comparison of Acute Treatments in Cancer Hemostasis (CATCH) trial to describe the impact of rVTE and bleeding events on health-related quality of life. METHODS: The three-level EuroQol five-dimensional questionnaire (EQ-5D) data were collected monthly for up to 7 months in patients starting anticoagulation for newly diagnosed VTE. Analyses were designed to describe the impact of rVTE and bleeding on EQ-5D scores while controlling for effects of covariates such as background and clinical variables and longitudinal changes. A repeated-measures model with specification of the variance-covariance matrix to characterize the intrapatient correlation was used to estimate the utility values. The impact of an rVTE or a bleeding event was assumed to be reflected in the utility value when it occurred within 2 weeks from a planned data collection point. RESULTS: Data were available from 883 patients. A total of 76 rVTE and 159 bleeding events occurred during follow-up. rVTE had a significant impact on EQ-5D scores, with a decrement of -0.075 on the basis of our reference case (male, no metastasis, Eastern Cooperative Oncology Group score = 1, Western European), but different patients might have different decrements. Bleeding events had a smaller (nonstatistically significant) impact on EQ-5D scores. CONCLUSIONS: This data set study has quantified the decline in EQ-5D scores associated with experiencing rVTE or bleeding events in cancer patients. These results indicate the net gain in quality of life and impact on cost-effectiveness of secondary VTE prevention.
Authors: Alok A Khorana; Nigel Mackman; Anna Falanga; Ingrid Pabinger; Simon Noble; Walter Ageno; Florian Moik; Agnes Y Y Lee Journal: Nat Rev Dis Primers Date: 2022-02-17 Impact factor: 65.038
Authors: Floris T M Bosch; Frits I Mulder; Pieter Willem Kamphuisen; Saskia Middeldorp; Patrick M Bossuyt; Harry R Büller; Nick van Es Journal: Blood Adv Date: 2020-10-27
Authors: Aurélien Delluc; Sébastien Miranda; Paul den Exter; Martha Louzada; Adriano Alatri; Shin Ahn; Manuel Monreal; Alok Khorana; Menno V Huisman; Philip S Wells; Marc Carrier Journal: Haematologica Date: 2019-07-04 Impact factor: 9.941
Authors: Michela Giustozzi; Jean M Connors; Ana Belen Ruperez Blanco; Sebastian Szmit; Nicolas Falvo; Alexander T Cohen; Menno Huisman; Rupert Bauersachs; Francesco Dentali; Cecilia Becattini; Giancarlo Agnelli Journal: J Thromb Haemost Date: 2021-07-29 Impact factor: 16.036
Authors: Frits I Mulder; Matteo Candeloro; Pieter W Kamphuisen; Marcello Di Nisio; Patrick M Bossuyt; Noori Guman; Kirsten Smit; Harry R Büller; Nick van Es Journal: Haematologica Date: 2019-01-03 Impact factor: 11.047